Previous Close | 2.9500 |
Open | 3.0000 |
Bid | 0.0000 x 1300 |
Ask | 0.0000 x 800 |
Day's Range | 2.8606 - 3.0300 |
52 Week Range | 1.9900 - 11.5900 |
Volume | |
Avg. Volume | 1,660,181 |
Market Cap | 563.862M |
Beta (5Y Monthly) | 0.92 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.6640 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.41 |
Subscribe to Yahoo Finance Plus to view Fair Value for NKTR
Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. This webcast will be available for replay un
Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual Meeting.